Catalytic Antibody (Catabody) Platform for Age-Associated Amyloid Disease: From Heisenberg’s Uncertainty Principle to the Verge of Medical Interventions
Publication date: Available online 26 November 2019Source: Mechanisms of Ageing and DevelopmentAuthor(s): Stephanie A. Planque, Richard J. Massey, Sudhir PaulAbstractQuantum mechanics-based design of useful catalytic antibodies (catabodies) failed because of the uncertain structure of the dynamic catalyst-substrate complex. The Catabody Platform emerged from discovery of beneficial germline gene catabodies that hydrolyzed self-proteins by transient covalent pairing of the strong catabody nucleophile with a weak target protein electrophile. Catabodies have evolved by Darwinian natural selection for protection against misfolded self-proteins that threatened survival by causing amyloid disease. Ancient antibody scaffolds upregulate the catalytic activity of the antibody variable (V) domains. Healthy humans universally produce beneficial catabodies specific for at least 3 misfolded self-proteins, transthyretin, amyloid β peptide and tau protein. Catabody are superior to ordinary antibodies because of catalyst reuse for thousands of target destruction cycles with little or no risk of causing inflammation, a must for non-toxic removal of abundant targets such as amyloids. Library mining with electrophilic target analogs (ETAs) isolates therapy-grade catabodies (fast, specific). Ex vivo- and in vivo-verified catabodies specific for the misfolded protein are available to dissolve brain, cardiac and vertebral amyloids. Immunization with ETAs overcomes important ordinary vaccine l...
Worldwide use of pneumococcal conjugate vaccines (PCVs) had reduced the incidence of pneumonia and invasive pneumococcal disease (IPD) in children.1,2 Despite increasing vaccine coverage and a reduction in the prevalence of IPD, Streptococcus pneumoniae remains a significant cause of non-Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (HUS) in children.3 HUS is characterized by the presence of the clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
Publication date: Available online 28 May 2020Source: The LancetAuthor(s): Nelson Lee, Allison McGeer
AbstractGlioma is the most common primary tumor of the nervous system, and approximately 50% of patients exhibit the most aggressive form of the cancer, glioblastoma. Currently, considerable research in glioblastoma therapeutics is aimed at developing vaccines or drugs to target key molecules for combating this disease. Studies on plant natural products from spices, vegetables, fruits, teas, and traditional medicinal herbs display that these plant-derived natural products can act as effective antioxidant and anti-tumor agents. The advancements in metabolomics and in genomics have enabled researchers to better evaluate the ...
Moderna Inc said on Friday it had started dosing patients in a mid-stage study with its experimental coronavirus vaccine and eventually plans to enroll 600 patients for the trial.
Scientists are developing drugs to stop the coronavirus. Here's what's promising and what isn't.
Publication date: Available online 28 May 2020Source: Veterinary MicrobiologyAuthor(s): Yuying Han, Libao Xie, Mengqi Yuan, Yuteng Ma, Huimin Sun, Yuan Sun, Yongfeng Li, Hua-Ji Qiu
The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
One has to be cautious about studies in which metabolism is broken in some way, and symptoms of aging start to appear earlier as a result. Whether or not this has any relevance to normal aging is dependent on the fine details of the biochemistry involved, and can often be argued either way even by those with the most knowledge in the field. Aging is an accumulation of damage and dysfunction in cells and tissues. Many genetic alterations and toxins that disrupt cell metabolism will lead to damage and dysfunction, and thus conditions that appear similar to those of aging. But unless it is the same forms and distribution of d...
As the worldwide death toll from the novel coronavirus continues to rise, scientists across the globe are racing to find a vaccine.